石药集团:EGFR ADC启动EGFRw NSCLC三期临床

医药笔记
Mar 03

▎Armstrong2026年3月2日,石药集团在Clinicaltrials.gov网站上注册了EGFR ADC新药SYS6010治疗经治EGFR野生型NSCLC的三期临床试验SYNSTAR03。该三期临床计划入组686例局部复发性或转移性EGFR野生型非鳞状NSCLC患者,预计2027年底初步完成。今年1月,石药集团在Clinicaltrials.gov网站上注册了SYS6010+奥希替尼联合...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10